Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,892
  • Shares Outstanding, K 73,682
  • Annual Sales, $ 3,350 K
  • Annual Income, $ -40,020 K
  • 60-Month Beta 1.52
  • Price/Sales 22.25
  • Price/Cash Flow N/A
  • Price/Book 3.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9800 +4.08%
on 05/01/20
1.1900 -14.29%
on 05/13/20
-0.0600 (-5.56%)
since 04/29/20
3-Month
0.6200 +64.52%
on 03/16/20
1.1900 -14.29%
on 05/13/20
+0.0386 (+3.93%)
since 02/28/20
52-Week
0.6200 +64.52%
on 03/16/20
1.9300 -47.15%
on 12/13/19
+0.1988 (+24.21%)
since 05/29/19

Most Recent Stories

More News
CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4

, /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at . The conference will...

CTIC : 1.0200 (-0.97%)
Lineage Cell: 1Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a first-quarter loss of $8.4 million, after reporting a profit in the same period a year earlier.

CTIC : 1.0200 (-0.97%)
CTI BioPharma Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended .

CTIC : 1.0200 (-0.97%)
CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind,...

CTIC : 1.0200 (-0.97%)
Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com

The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

CTIC : 1.0200 (-0.97%)
GERN : 1.6100 (unch)
NVS : 87.43 (+1.33%)
CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Needham Healthcare Conference at 10:40 a.m. EDT. The conference will be held...

CTIC : 1.0200 (-0.97%)
Lineage Cell: 4Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $4.5 million in its fourth quarter.

CTIC : 1.0200 (-0.97%)
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019.

CTIC : 1.0200 (-0.97%)
CTI BioPharma Announces Closing of Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, CTI BioPharma sold and issued an aggregate of 15,698,995...

CTIC : 1.0200 (-0.97%)
CTI BioPharma Announces Commencement of Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights...

CTIC : 1.0200 (-0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CTIC with:

Business Summary

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its...

See More

Key Turning Points

2nd Resistance Point 1.0600
1st Resistance Point 1.0400
Last Price 1.0200
1st Support Level 1.0000
2nd Support Level 0.9800

See More

52-Week High 1.9300
Fibonacci 61.8% 1.4296
Fibonacci 50% 1.2750
Fibonacci 38.2% 1.1204
Last Price 1.0200
52-Week Low 0.6200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar